SLC6A3 and depressive symptom measurement: Subjects with lower striatal DAT binding within 2 years of the clinical diagnosis of PD were more likely to develop motor-related disability, as well as cognitive impairment, psychosis, and depression after more than 5 years of follow-up [43].